Antiretroviral Treatment Simplification With 3 NRTIs or 2 NRTIs Plus Nevirapine in HIV-1-Infected Patients Treated With Successful First-Line HAART

OBJECTIVES:To assess the virologic noninferiority of an antiretroviral treatment simplification with coformulated zidovudine/lamivudine/abacavir (group 1) vs. coformulated zidovudine/lamivudine plus nevirapine (group 2) in HIV-1-infected patients receiving successful first-line highly active antiret...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of acquired immune deficiency syndromes (1999) 2005-07, Vol.39 (3), p.313-316
Hauptverfasser:	Bonjoch, Anna, Paredes, Roger, Galvez, Juan, Miralles, Celia, Videla, Sebastia, Martínez, Eva, Miranda, Jose, Muñoz-Moreno, Jose Antonio, Torre, Javier De la, Prieto, Arturo, Vilades, Consuelo, Clotet, Bonaventura
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antiretroviral drugs Antiretroviral Therapy, Highly Active Biological and medical sciences CD4 Lymphocyte Count Dideoxynucleosides - administration & dosage Drug Resistance, Viral - genetics Drug therapy Female Fundamental and applied biological sciences. Psychology Genotype HIV HIV Infections - drug therapy HIV Infections - immunology HIV Infections - virology HIV-1 - drug effects HIV-1 - genetics Human immunodeficiency virus Human viral diseases Humans Infectious diseases Lamivudine - administration & dosage Male Medical sciences Microbiology Miscellaneous Mutation Nevirapine - administration & dosage Patient Compliance Patient Satisfaction Prospective Studies Quality of Life Reverse Transcriptase Inhibitors - administration & dosage RNA, Viral - blood Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Virology Zidovudine - administration & dosage
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	OBJECTIVES:To assess the virologic noninferiority of an antiretroviral treatment simplification with coformulated zidovudine/lamivudine/abacavir (group 1) vs. coformulated zidovudine/lamivudine plus nevirapine (group 2) in HIV-1-infected patients receiving successful first-line highly active antiretroviral therapy. METHODS:This is a prospective, multicenter, open-label, comparative, randomized, noninferiority study. A delta of 15% for differences in virologic suppression
ISSN:	1525-4135 1944-7884
DOI:	10.1097/01.qai.0000164249.33851.3a